ANASTROZOLE (120511-73-1)
Anastrozole, brand name is Arimidex. It is used with other treatments, such as surgery or radiation, to treat early breast cancer in women who have experienced menopause (change of life; end of monthly menstrual periods). This medication is also used in women, who have experienced menopause,
| Status: | In Mass Production |
| Unit: | 25kg/Drum |
| Capacity: | 1380kg/month |
Anastrozole (120511-73-1) video
Anastrozole (120511-73-1) Description
Anastrozole, brand name is Arimidex. It is used with other treatments, such as surgery or radiation, to treat early breast cancer in women who have experienced menopause (change of life; end of monthly menstrual periods). This medication is also used in women, who have experienced menopause, as a first treatment of breast cancer that has spread within the breast or to other areas of the body. This medication is also used to treat breast cancer in women whose breast cancer has worsened after taking tamoxifen (Nolvadex). Anastrozole is in a class of medications called nonsteroidal aromatase inhibitors. It works by decreasing the amount of estrogen the body makes. This can slow or stop the growth of many types of breast cancer cells that need estrogen to grow.
Anastrozole is a potent and selective non-steroidal aromatase inhibitor indicated for the treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. Many breast cancers have estrogen receptors and growth of these tumors can be stimulated by estrogens. In post-menopausal women, the principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues, such as adipose tissue, with further conversion of estrone to estradiol. Many breast cancers also contain aromatase; the importance of tumor-generated estrogens is uncertain. Treatment of breast cancer has included efforts to decrease estrogen levels by ovariectomy premenopausally and by use of anti-estrogens and progestational agents both pre- and post-menopausally, and these interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole is a potent and selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
Anastrozole (120511-73-1) Specifications
| Product Name | Anastrozole |
| Chemical Name | ICI-D-1033;ARIMIDEX;1-[3,5-DI-(1-METHYL-1-CYANO)-ETHYL]-BENZYL-1,2,4-TRIAZOLE, Anastrozol |
| Brand Name | Arimidex |
| Drug Class | non-steroidal aromatase inhibitor |
| CAS Number | 120511-73-1 |
| InChIKey | YBBLVLTVTVSKRW-UHFFFAOYSA-N |
| Molecular Formula | C17H19N5 |
| Molecular Weight | 293.374 g/mol |
| Monoisotopic Mass | 293.164 g/mol |
| Melting Point | 130.14 °C |
| Freezing Point | No data available |
| Biological Half-Life | 50 hours |
| Color | White powder |
| Solubility | water solubility 0.5 mg/mL |
| Storage Temperature | RT |
| Application | For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome. |
BuyAAS 